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LETTER TO THE EDITOR Open Access
HPV vaccines and cancer prevention, science
versus activism
Lucija Tomljenovic1*, Judy Wilyman2, Eva Vanamee3, Toni Bark4 and Christopher A Shaw1
Abstract
The rationale behind current worldwide human papilloma virus (HPV) vaccination programs starts from two basic
premises, 1) that HPV vaccines will prevent cervical cancers and save lives and, 2) have no risk of serious side
effects. Therefore, efforts should be made to get as many pre-adolescent girls vaccinated in order to decrease the
burden of cervical cancer. Careful analysis of HPV vaccine pre- and post-licensure data shows however that both of
these premises are at odds with factual evidence and are largely derived from significant misinterpretation of
available data.
Letter
The recent Editorial by Silvia de Sanjosé* [1] is problem-
atic from a variety of perspectives. Mainly, it attempts to
portray a complex issue as a simple dichotomy between
supposedly unjustified “anti-HPV vaccine activism” and
alleged absolute science which has presumably provided
indisputable evidence on HPV vaccine safety and
efficacy.
In spite of much unwarranted and premature opti-
mism, the fact is however that HPV vaccines have not
thus far prevented a single case of cervical cancer (let
alone cervical cancer death). Instead, what the clinical
trials have shown is that HPV vaccines can prevent some
of the pre-cancerous CIN 2/3 lesions associated with
HPV-16 and HPV-18 infection, a large fraction of which
would spontaneously resolve regardless of the vaccin-
ation status [2-4]. For example, in adolescent women
aged 13 to 24 years, 38% of CIN 2 resolve after one year,
63% after two and 68% after three years [5]. Moreover,
the validity of CIN 2 being a cancer precursor is ques-
tionable due to high misclassification rates and poor
intra- and inter-observer reproducibility in diagnosis, as
well as high regression rates [6-9]. According to Castle
et al. [7] CIN 2 is the least reproducible of all histo-
pathologic diagnoses and may in part reflect sampling
error. While CIN 3 is a more reliable marker for cancer
progression than CIN 2, the use of this marker is not
without caveats [2,10].
Indeed, the optimistic assumption that HPV vaccina-
tion (even if proven effective against cervical cancer as
claimed), will result in 70% reduction of cervical cancers
appears to be largely based on premature, exaggerated
and invalid surrogate marker-based extrapolations
[2,11]. Crucially, these assumptions failed to take into
account several important real-world factors such as:
(1) reliability of surrogate-markers (i.e., whether they
can accurately measure what they are purport to
measure);
(2) efficacy against oncogenic HPV strains not covered
by the vaccine;
(3) possibility of increased frequency of infections with
these types;
(4) efficacy in women acquiring multiple HPV types;
(5) effects in women with pre-existing HPV infections
It is also noteworthy that Merck’s HPV vaccine Gardasil
received priority Fast Track approval by the U.S. Food and
Drug Administration (FDA) after a 6-month review
process, despite the fact that it failed (and still continues
to fail) to meet a single one of the four criteria required by
the FDA for Fast Track approval. Gardasil is demonstrably
neither safer nor more effective than Pap screening com-
bined with the loop electrosurgical excision procedure
(LEEP) in preventing cervical cancers, nor can it improve
the diagnosis of serious cervical cancer outcomes [12]. In
this regard, Gerhardus and Razum have recently noted
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that the “. . .unwarranted confidence in the new [HPV]
vaccines led to the impression that there was no need to
actually evaluate their effectiveness” [11].
Similarly, the notion that HPV vaccines have an
impressive safety profile can only be supported by highly
flawed design of safety trials [2,13] and is contrary to
accumulating evidence from vaccine safety surveillance
databases and case reports which continue to link HPV
vaccination to serious adverse outcomes (including
death and permanent disabilities) [2,4,14]. For example,
compared to all other vaccines in the U.S. vaccination
schedule, Gardasil alone is associated with 61% of all
serious adverse reactions (including 63.8% of all deaths
and 81.2% cases of permanent disability) in females
younger than 30 years of age [12].
Although a report to a vaccine safety surveillance system
does not by itself prove that the vaccine caused an adverse
reaction, the unusually high frequency of adverse reactions
related to HPV vaccines reported worldwide, as well as
their consistent pattern (i.e. nervous system-related disor-
ders rank the highest in frequency), points to a potentially
causal relationship [2]. Furthermore, matching the data
from vaccine surveillance databases is an increasing num-
ber of case reports documenting similar serious adverse
reactions associated with HPV vaccine administration,
with nervous system and autoimmune disorders being the
most frequently reported in the medical literature [15-24].
In summary, the optimistic claims that HPV vaccines will
prevent cervical cancers and save lives, and that they are
extremely safe, rest on assumptions which are misinter-
preted and presented to the public as factual evidence. We
thus conclude that further reduction of cervical cancers
might be best achieved by optimizing cervical screening
(which carries no serious health risks) and targeting other
factors of the disease rather than by the reliance on vac-
cines with questionable efficacy and safety profiles [2,25].
To those who wish to promote HPV vaccination as a
means for reducing cervical cancer burden, perhaps the
following should be asked:
1. HPV vaccines have not been demonstrated to
prevent any cervical cancers so why are they being
promoted as cervical cancer vaccines?
2. If the majority of HPV infections and a great
proportion of pre-cancerous lesions clear
spontaneously and without medical treatment and
are thus not a reliable indication of cancer later in
life, then how can these end-points be used as a
reliable indicator of the number of cervical cancer
cases that will be prevented by HPV vaccines?
3. How can the clinical trials make an accurate estimate
of the risk associated with HPV-vaccines if they are
methodologically biased to produce type-2 errors
(false negatives [2,4,13])?
4. Can a passive monitoring system such as that used
by most vaccine surveillance systems world-wide
allow the medical regulatory agencies to make
accurate estimates on the real frequency of
HPV-vaccine related adverse reactions?
5. Can an accurate estimate of the real frequency of
HPV-vaccine related adverse reactions be made if
appropriate follow-up and thorough investigation of
suspected vaccine related ADRs is not conducted but
instead, these cases are a-priori dismissed as being
unrelated to the vaccine?
6. Why are women not informed of the fact that in
some circumstances (i.e., prior exposure to
vaccine-targeted and non-targeted HPV types),
HPV vaccination may accelerate the progression
of cervical abnormalities [4,26-28]?
7. How can women make a fully informed decision
about whether or not to consent to vaccination if
crucial information regarding HPV vaccine efficacy
and safety is not being disclosed to them?
8. Should the medical health regulators and authorities
rely solely on data provided by the vaccine
manufacturers to make vaccine-policy decisions and
recommendations [12,29]?
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